Pro-ocular™

Case Studies

128

Patients Over Two Years

Completed Phase 2 Studies

Peer Reviewed Publications

Pro-ocular® for Contact Lens Dry Eye

Baseline

Dose + 6 min.

Dose + 2 hours

Baseline:

Lens sticking to eye and little tear film in front or behind contact lens

Same Eye, Dose + 15 min.:

New tear film enables lens to float – eliminating dry eye and increasing contact lens wear time

Pro-ocular® for oGvHD Severe Dry Eye

Before Pro-Ocular

Functionally blind – seeing 20/250 with “inoperable” cataracts due to fragile corneas

2 Weeks on Pro-ocular

Getting relief in symptoms, still functionally blind

1 Year on Pro-ocular

Months 10 &11 bi-lateral cataract surgery while on Pro-ocular with vision correct to 20/20

Subject reported 6 years later seeing 20/20 in both eyes while using Pro-ocular

Join Our Mission

Signal12 is planning to facilitate Phase 3 clinical trials in 2025 and bring Pro-ocular™ to market.

Pro-ocular™
Clinical Trials
Company
Leadership

Signal12 Inc.

Signal12 is a Phase 3-ready ophthalmic drug company. Our proprietary topical drug, Pro-ocular™, has proven safe and effective in Phase 2 clinical studies, demonstrating significant reductions in the signs and symptoms of ocular Graft-versus-Host Disease (oGvHD)—a chronic, debilitating condition following an allogeneic stem cell transplant. Pro-ocular™ is the only effective treatment for oGvHD, employing transappendageal delivery to precisely target the ophthalmic branch of the trigeminal nerve

Signal12 is actively raising capital to complete its Phase 3 clinical trials and bring Pro-ocular™ to market. For information on investment opportunities, please email Neil Edwards at [email protected]. The company has offices in Greenwich, CT and Boston, MA.